Survey
2 Week Delay: A survey on the PSMA-PET Imaging Agents with a focus on Pluvicto (Novartis Lu-PSMA-617) and PNT-2002 (Lu-PSMA-I&T)
Ticker(s): NVS, LNTH, PNTData includes 30 qualified oncologists out of 75 attempts.
- Community
- Academic
How does your PSMA-PET imaging volume compare with 6 months ago?
How do you anticipate your PSMA-PET imaging volumes to change over the next 6 months?
What is the breakdown of your current use of different PSMA-PET imaging agents?
Please elaborate on the reason(s) for the use of your preferred agent(s) in the previous question:
Are you currently using, or are you planning to use PSMA-PET imaging off-label, such as for disease monitoring or earlier stage patients?
How many patients have you started on Pluvicto (Novartis Lu-PSMA-617) in the commercial setting (excluding patients treated on clinical trials)?
How many patients do you have who are waiting to start on Pluvicto, but are unable to receive product due to supply shortages?
Please elaborate on your previous response?
What is the current wait time (in months) to start a patient on Pluvicto at your center?
Assuming the PSMAfore (Lu-PSMA-617) and SPLASH (PNT-2002) trials are successful and demonstrate a statistically significant improvement in PFS vs retreatment with androgen-directed therapy, what proportion of your 2L mCRPC patients would you consider good candidates for Lu-PSMA radiotherapy?
What do you see as the main differences between Pluvicto (Lu-PSMA-617) and PNT-2002 (Lu-PSMA-I&T)?
Assuming both Pluvicto (Lu-PSMA-617) and PNT-2002 (Lu-PSMA-I&T) are approved in 2L mCRPC, what do you anticipate the breakdown of your use of the two products would be?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
